TW429262B - C5a receptor antagonists having substantially no agonist activity - Google Patents

C5a receptor antagonists having substantially no agonist activity

Info

Publication number
TW429262B
TW429262B TW083111578A TW83111578A TW429262B TW 429262 B TW429262 B TW 429262B TW 083111578 A TW083111578 A TW 083111578A TW 83111578 A TW83111578 A TW 83111578A TW 429262 B TW429262 B TW 429262B
Authority
TW
Taiwan
Prior art keywords
analogues
derivatives
receptor antagonists
agonist activity
analogue
Prior art date
Application number
TW083111578A
Other languages
Chinese (zh)
Inventor
Oostrum Jan Van
William C Boyar
Nicholas G Galakatos
Jane V Peppard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of TW429262B publication Critical patent/TW429262B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.
TW083111578A 1993-12-06 1994-12-13 C5a receptor antagonists having substantially no agonist activity TW429262B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16259193A 1993-12-06 1993-12-06

Publications (1)

Publication Number Publication Date
TW429262B true TW429262B (en) 2001-04-11

Family

ID=22586301

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083111578A TW429262B (en) 1993-12-06 1994-12-13 C5a receptor antagonists having substantially no agonist activity

Country Status (15)

Country Link
EP (1) EP0733107A1 (en)
JP (1) JPH09506258A (en)
CN (1) CN1142854A (en)
AU (1) AU698919B2 (en)
BR (1) BR9408265A (en)
CA (1) CA2176825A1 (en)
FI (1) FI962319A (en)
HU (1) HUT75990A (en)
IL (1) IL111792A0 (en)
MX (1) MXPA99008669A (en)
NO (1) NO962348L (en)
NZ (1) NZ274917A (en)
TW (1) TW429262B (en)
WO (1) WO1995016033A1 (en)
ZA (1) ZA949647B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI767415B (en) * 2020-11-18 2022-06-11 中國醫藥大學 Automatic blood analysis system and automatic blood analysis method

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
WO1996039503A1 (en) * 1995-06-05 1996-12-12 Novartis Ag C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION
MX9706181A (en) * 1995-12-13 1997-11-29 Northern Telecom Ltd Integrated cellular voice and digital packet data telecommunications systems and methods for their operation.
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
CN113150106B (en) * 2021-04-26 2022-08-16 华中农业大学 Antibacterial peptide derived from complement component C5a and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (en) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptide antagonists for the C5a anaphylatoxin
JP2703764B2 (en) * 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション Monoclonal antibody against complement component C5a

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI767415B (en) * 2020-11-18 2022-06-11 中國醫藥大學 Automatic blood analysis system and automatic blood analysis method

Also Published As

Publication number Publication date
ZA949647B (en) 1995-06-06
JPH09506258A (en) 1997-06-24
MXPA99008669A (en) 2004-09-01
HUT75990A (en) 1997-05-28
NO962348L (en) 1996-08-05
NO962348D0 (en) 1996-06-05
BR9408265A (en) 1996-12-10
HU9601538D0 (en) 1996-07-29
EP0733107A1 (en) 1996-09-25
IL111792A0 (en) 1995-01-24
FI962319A0 (en) 1996-06-03
FI962319A (en) 1996-06-03
WO1995016033A1 (en) 1995-06-15
CN1142854A (en) 1997-02-12
AU698919B2 (en) 1998-11-12
NZ274917A (en) 1998-03-25
AU8002594A (en) 1995-06-27
CA2176825A1 (en) 1995-06-15

Similar Documents

Publication Publication Date Title
Ravizza et al. Inactivation of caspase‐1 in rodent brain: a novel anticonvulsive strategy
Capuron et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy
Vuolteenaho et al. Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage Role of endogenous IL‐1 inhibitors
Lenczowski et al. Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats
Konno et al. Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus
UA27776C2 (en) Quinuclidine derivatives, pharmaceutically acceptable saults thereof which are substance p receptor antagonists in mammals, pharmaceutical composition possessing antagonist activity on substance p in mammals
FI963101A (en) Use of anti-TNF antibodies as drugs for the treatment of diseases in which serum interleukin-6 levels are elevated
EP0340109A3 (en) Anti-t-cell receptor determinants as autoimmune disease treatment
ATE415173T1 (en) PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE
NO951613L (en) Non-peptidyl tachykinin receptor antagonists
NO974258L (en) IL-17 receptor
Parente et al. Relationship between the anti-phospholipase and anti-inflammatory effects of glucocorticoid-induced proteins
CO5011096A1 (en) MEDICINES CONTAINING ANTAGONISTS OF THE 5-HT3 RECEPTOR FOR THE TREATMENT OF IBS
SE9503924D0 (en) Novel opioid peptides
ATE258444T1 (en) THERAPEUTIC CHEMOKINE RECEPTOR ANTAGONISTS
PT735818E (en) INFLAMMATORY PROTEINS OF MACROFAGOS PIM-3 PIM-4 AND PIM-1Y
GEP20074267B (en) Receptor nucleic acids and polypeptides
DK1588706T3 (en) Valsartan tablet
ATE175347T1 (en) USE OF A SEROTONIN AGONIST IN COMBINATION WITH A TACHYKINE RECEPTOR ANTAGONIST FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF MIGRAINE
TW429262B (en) C5a receptor antagonists having substantially no agonist activity
Dourish et al. Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat
KR980002066A (en) Mutant human growth hormone and uses thereof
Furuzawa-Carballeda et al. Polymerized-Type I Collagen Induces Upregulation of Foxp3-Expressing CD4 Regulatory T Cells and Downregulation of IL-17-Producing CD4 T Cells (Th17) Cells in Collagen-Induced Arthritis
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
JP2007534746A (en) IL-6 for the treatment or prevention of chemotherapy-induced neuropathy

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees